3E Therapeutics Corporation Report issue

For profit Phase 1 Phase 2
Founded: La Jolla CA United States (2013)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2015
NCT02377895
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

iodixanol (visipaque) (1 trial)

Drugs in Phase 1 Trials (1)

ricolinostat (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2